A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Hari Talreja, Jasmine Tan, Matt Dawes, Sharen Supershad, Kannaiyan S Rabindranath, James P. Fisher, Sajed Valappil, Veronica van der Merwe, Lisa Wong, Walter van der Merwe, Julian Paton
2020PubMed25 citations
Abstract
There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use.
Topics & Concepts
MedicineAngiotensin Receptor BlockersCoronavirus disease 2019 (COVID-19)Angiotensin-converting enzymeDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Renin–angiotensin system2019-20 coronavirus outbreakAdverse effectAngiotensin IICoronavirusAngiotensin receptorInternal medicinePharmacologyReceptorVirologyInfectious disease (medical specialty)Blood pressureOutbreakCOVID-19 Clinical Research StudiesVitamin C and Antioxidants ResearchLong-Term Effects of COVID-19